Daily Pharma News - 12 October 2026
India's drug regulator tightened oversight on two fronts today - curbing prescription drug advertising by retailers and questioning the formulary listings of unapproved medicines - while Kerala pushed drug affordability through direct procurement. Internationally, WHO issued its first childhood obesity guidelines, the FDA approved the first therapy for symptomatic dermographism, and China's NMPA cleared a novel bispecific antibody trial for inflammatory bowel disease. Here is the full analysis.
India Proposes Strict Curbs on Prescription Drug Advertising by Retailers and Wholesalers
The Union Health Ministry has proposed a major amendment to the Drugs Rules, 1945 through draft GSR 861(E), seeking to prohibit retail and wholesale licence holders from advertising Schedule H, H1 and X drugs without central sanction. The move directly targets the growing direct-to-consumer promotion of prescription medicines - including GLP-1 weight-loss drugs such as Ozempic (semaglutide) and Mounjaro (tirzepatide) - which are legally meant to be dispensed only on prescription. The draft has been opened for public comments for 30 days.
For Indian pharmacy students, this is a live case study in drug advertising regulation and Schedule H/H1/X classification under the Drugs Rules, 1945. If notified, the amendment would reshape how pharmacies and distributors promote prescription medicines in India, reinforcing the pharmacist's role as a regulated dispenser rather than a promoter of prescription products.
DCGI Seeks Explanation from IPC Over Unapproved Medicines Listed in NFI 2026
The Drugs Controller General of India (DCGI) has sought an explanation from the Indian Pharmacopoeia Commission (IPC) after an Economic Times review found at least five medicines listed in the National Formulary of India (NFI) 2026 that apparently lack Central Drugs Standard Control Organisation (CDSCO) approval. NFI 2026, released on 21 September with 653 monographs, is the reference prescribers and pharmacists consult for rational medicine use - so listing unapproved products, including methylene blue and flumazenil injections, raises serious questions about the formulary's vetting process.
This development matters for pharmacy practice in India because the National Formulary of India underpins drug selection, hospital formularies and pharmacovigilance. Students should note the tension it exposes between pharmacopoeial standards-setting by the IPC and marketing authorisation by the CDSCO - two pillars of Indian drug regulation that must stay aligned.
ICMR-CHAMP: India's First High-Altitude Medicine Research Centre Laid in Keylong
Health Minister J.P. Nadda laid the foundation stone for ICMR-CHAMP (Centre for High Altitude Medicine and Public Health) at Keylong in Himachal Pradesh - the Indian Council of Medical Research's first dedicated centre for high-altitude medicine and public health research. The centre will work on mountain medicine, climate-sensitive diseases affecting high-altitude populations, telemedicine models and drone-based medical logistics for remote terrain.
For pharmacy students, ICMR-CHAMP opens a new frontier: pharmaceutical care in extreme environments, cold-chain logistics for remote districts, and the growing role of telemedicine and drone delivery in last-mile drug distribution. Watch for research fellowships and project openings at this centre in the coming years.
Kerala Slashes Insulin, Erythropoietin and SMA Drug Prices Through Direct Manufacturer Deals
The Kerala Medical Services Corporation (KMSCL) has negotiated steep direct-procurement discounts: a 10 ml insulin vial is down to Rs 73 from Rs 99.60, erythropoietin to Rs 80 from Rs 110, and Natco Pharma's generic risdiplam for spinal muscular atrophy (SMA) to Rs 8,000 per bottle from Rs 5.52 lakh. By cutting out intermediaries and buying straight from manufacturers, Kerala's public drug-procurement model continues to show how state agencies can force drug prices down for patients.
This continues India's broader drug-affordability push - from NPPA price caps and cancer-drug margin controls to Tamil Nadu's and Kerala's pooled procurement models. For B Pharm and M Pharm students, KMSCL's negotiation tactics are a textbook lesson in pharmaceutical supply-chain management and the economics of essential medicines.
NMPA Clears InnoCare's ICP-B161 Bispecific Antibody Trial for Inflammatory Bowel Disease
China's National Medical Products Administration (NMPA), through its Center for Drug Evaluation, has approved the Investigational New Drug (IND) application for ICP-B161 - InnoCare Pharma's long-acting bispecific antibody that simultaneously targets TL1A and IL-23p19 for inflammatory bowel disease (IBD). Preclinical data reportedly show synergistic cytokine suppression by blocking both pathways at once.
The approval spotlights China's fast-moving biologics pipeline and the industry's shift toward bispecific antibodies that hit two disease targets in one molecule - a trend Indian pharmacology students should follow closely as biosimilar and novel-biologic manufacturing grows in India too.
FDA Approves Rhapsido (Remibrutinib): First Therapy for Symptomatic Dermographism
The US Food and Drug Administration has approved Novartis's Rhapsido (remibrutinib), an oral selective Bruton's tyrosine kinase (BTK) inhibitor, for symptomatic dermographism uncontrolled by H1 antihistamines - the first therapy ever approved for this condition, in which light scratching of the skin triggers raised, itchy welts. In trials, 29.3% of patients achieved complete hive resolution at week 12, compared with 14% on placebo.
This is a landmark in dermatology and immunology: a targeted BTK inhibitor - a drug class previously associated with B-cell cancers - now repurposed for a chronic skin condition driven by mast-cell activation. It is a vivid example of how mechanism-based drug repurposing creates first-in-class therapies, exactly the kind of story pharmacology students should track.
WHO Childhood Obesity Guidelines: No Obesity Medicines, GLP-1 Drugs or Surgery for Children Under 10
The World Health Organization has released its first-ever guidelines on childhood obesity, advising against the use of obesity medicines, GLP-1 drugs, bariatric surgery and weight-loss devices in children under 10 years. For adolescents aged 10-19, medicines may be considered only after structured lifestyle programmes have failed. The guidelines put behavioural and nutritional interventions first across all ages.
The timing is striking alongside India's draft advertising curbs on GLP-1 drugs: both stories reflect a global regulatory reckoning with the rapid spread of weight-loss medicines. Pharmacy students should understand why guidelines draw age lines - the evidence base for obesity medicines in young children is thin, while lifestyle intervention remains the proven foundation.
Conclusion
Today's news ties together three themes pharmacy students must master: regulation, access and innovation. India's twin moves - the GSR 861(E) advertising draft and the DCGI's scrutiny of the NFI - show regulators closing gaps between what is prescribed, promoted and approved. Kerala's procurement wins prove that smart buying, not just price caps, can make essential medicines affordable. And the Rhapsido approval, ICP-B161 clearance and WHO obesity guidelines remind us that drug development and evidence-based guidance move together - new therapies earn their place only when the science supports them. For the Indian pharmacy classroom, 12 October 2026 is a rich day of real-world cases in pharmacoeconomics, regulatory affairs and rational therapeutics.
References
- The New Indian Express - Centre proposes strict curbs on advertising prescription drugs including GLP-1 medicines https://www.newindianexpress.com/amp/story/india/2026/Oct/09/centre-proposes-strict-curbs-on-advertising-prescription-drugs-including-glp-1-medicines
- Medical Gate Today - CDSCO/IPC: NFI 2026 medicine listings https://medgatetoday.com/cdsco-ipc-nfi-2026-medicine-listings/
- DD India - Health Minister Nadda to lay foundation stone for ICMR's first high-altitude health research centre in Keylong https://ddindia.co.in/2026/10/health-minister-nadda-to-lay-foundation-stone-for-icmrs-first-high-altitude-health-research-centre-in-keylong/
- FM Bharat - Kerala cuts drug procurement costs through direct manufacturer deals https://fmbharat.com/en/india/kerala-cuts-drug-procurement-costs-through-direct-manufacturer-deals
- TradingView (GlobeNewswire) - InnoCare announces approval of clinical trial of bispecific antibody ICP-B161 targeting TL1A and IL-23p19 in China https://www.tradingview.com/news/globenewswire:17f704e02094b:0-innocare-announces-approval-of-clinical-trial-of-bispecific-antibody-icp-b161-targeting-tl1a-and-il-23p19-in-china/
- Biopharma Asia - FDA approves Rhapsido as first treatment for symptomatic dermographism https://biopharma-asia.com/sections/fda-approves-rhapsido-as-first-treatment-for-symptomatic-dermographism/
- Reuters - WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight https://www.reuters.com/business/healthcare-pharmaceuticals/who-endorses-lifestyle-changes-over-glp-1-drugs-child-obesity-fight-2026-10-07/